Quanlin Zhao

Dr. Quanlin Zhao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Renal Failure
Verified
Journal Article
Open access
YLYi Liu
Yi Liu
CAChuan An
Chuan An
PLPeilong Liu
Peilong Liu
FYFan Yang
Fan Yang
QZQuanlin Zhao
Quanlin Zhao
The safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors in elderly patients with diabetic kidney disease (DKD) is still controversial. This study aimed to analyze the safety of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus (T2DM) and DKD. We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to March 2023. Randomized controlled trials (RCTs) were included. Data including patient characteristics and interesting outcomes were extracted, and the dichotomous data and continuous variables were evaluated using risk ratio (RR) with 95% confidence intervals (CIs) and mean difference (MD) with 95% CIs, respectively. A total of 14 RCTs with 59874 participants were finally included. There were 38,252 males (63.9%) and 21,622 females (36.1%). The patients' mean age was > 64.6 years. SGLT2 inhibitors could delay the further decline of estimated glomerular filtration rate (eGFR) when eGFR ≥ 60 ml/min/1.73m2 (MD: 2.36; 95%CI [1.15-3.57]). SGLT2 inhibitors in elderly patients with eGFR < 60 ml/min/1.73m2 (RR: 0.86; 95%CI [0.67-1.11]) may have a relatively increased risk of acute kidney injury compared to eGFR ≥ 60 ml/min/1.73m2. SGLT2 inhibitors increased the incidence of genital mycotic infections (RR: 3.47; 95%CI [2.97-4.04]) and diabetic ketoacidosis (RR: 2.25; 95%CI [1.57-3.24]). Except for genital mycotic infections and diabetic ketoacidosis, other adverse reactions were few, indicating that SGLT2 inhibitors are relatively safe for elderly patients with T2DM and DKD. Safety and renoprotection may be diminished when SGLT2 inhibitors are used in elderly patients with eGFR < 60 ml/min/1.73m2.

14 October 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XLXiujuan Liu
Xiujuan Liu
HYHong-Lin Yin
Hong-Lin Yin
YLYan Li
Yan Li
HHHao Hao
Hao Hao
YLYang Liu
Yang Liu
QZQuanlin Zhao
Quanlin Zhao
Background. Salt‐sensitivity hypertensives (SSH) are an independent risk factor for cardiovascular disease. However, the mechanism of SSH is not clear. This study is aimed at constructing a competing endogenous RNA (ceRNA) network related to SSH. Methods. Data sets were collected from the Gene Expression Omnibus database (GEO) to extract data on salt sensitivity RNA of patients with or without hypertensives in GSE135111. Firstly, we analyzed differentially expressed genes (DEGs, log2FC ≥ 0.5 and P < 0.05) and differentially expressed lncRNAs (DELs, log2FC ≥1 and P<0.05) between SSH and salt‐sensitive normotension (SSN). Then, the gene ontology (GO), KEGG pathway enrichment analysis, and PPI network construction of DEGs were performed, and the hub genes in the PPI network by cytoHubba (12 methods) were screened out. Finally, a ceRNA network was constructed based on lncRNA‐miRNA‐mRNA pairs and hub genes. Results. 163 DEGs and 65 DELs were screened out. The GO and KEGG pathway analyses of DEGs were mainly enriched in metabolism (e.g., insulin secretion and cellular response to glucagon stimulus and peptidyl‐tyrosine dephosphorylation,) and plasma membrane signaling (e.g., cell adhesion and chemical synaptic transmission and integral component of membrane). Additionally, a ceRNA network, including 1 mRNA (EGLN3), 2 miRNAs (hsa‐miR‐17‐5p and hsa‐miR‐20b‐5p), and 1 lncRNA (C1orf143) was successfully constructed. Conclusions. In conclusion, the proposed ceRNA network may help elucidate the regulatory mechanism by which lncRNAs function as ceRNAs and contribute to the pathogenesis of SSH. Importantly, candidate lncRNAs, miRNAs, and mRNAs can be further evaluated as a potential therapeutic targets for SSH.

29 April 2022 in Medicine
Verified
Journal Article
Open access
FYFan Yang
Fan Yang
YDYouzi Dong
Youzi Dong
BLBaohua Li
Baohua Li
BNBobiao Ning
Bobiao Ning
QZQuanlin Zhao
Quanlin Zhao
Background: Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus. It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However, there is no consensus on DPP-4i's pancreatic safety due to a paucity of clinical evidence. The safe event appears to be easily overlooked. This review aims to evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes mellitus using the standard pairwise and network meta-analysis methods. Methods: MEDLINE, Embase, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials will be used to search for published literature on the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus, and clinical trial registries will be used to look for unpublished trials. Two independent reviewers will screen literature for eligibility, extract available data, and assess the risk of bias. All divergences will be resolved after rechecking the source papers and further discussion among the reviewers with a complete consensus before inclusion. The risk of bias will be assessed by the Cochrane bias risk tool, and the quality of evidence will be interpreted by the GRADE Working Group approach. We will use STATA16.0 and WinBUGS1.4.3 for paired meta-analysis and Bayesian network meta-analysis. Results: This study will evaluate the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus. Conclusion: This systematic review and network meta-analysis will evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes millitus. The findings of this study may supplement the evidence-based information on DPP-4i, improve existing understanding of this issue, and assist patients and clinicians in making better treatment decisions by raising their awareness of the problem. Protocol registration number: INPLASY202230014.

17 January 2024 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
YLYi Liu
Yi Liu
CAChuan An
Chuan An
XAXin Ai
Xin Ai
XZXinyu Zhang
Xinyu Zhang
LSLin Shi
Lin Shi
QZQuanlin Zhao
Quanlin Zhao
Piperacillin‑tazobactam is a clinically used antibiotic consisting of the semisynthetic penicillin piperacillin and the β‑lactamase inhibitor tazobactam. Piperacillin‑tazobactam is a broad‑spectrum antibiotic used clinically to treat infections caused by gram‑positive and gram‑negative aerobic and anaerobic bacteria. The most common adverse reactions are gastrointestinal symptoms and skin reactions. There have been a few reported cases of possible drug hypersensitivity, with thrombocytopenia as the most commonly observed adverse event. The present article reported a rare case of myocardial injury with heart failure following treatment of pneumonia with piperacillin‑tazobactam in a 75‑year‑old female patient. Specifically, this patient presented with fever, chills, flushing and tachypnea, in addition to elevated leukocyte, neutrophil, cardiac enzyme and brain natriuretic peptide levels. This patient also presented with a mild ST‑segment elevation on the electrocardiogram following piperacillin‑tazobactam treatment. Improvements in the aforementioned adverse reactions were observed and the underlying infection didn't come back following the discontinuation of piperacillin‑tazobactam treatment. Therefore, the present observations suggest that piperacillin‑tazobactam may have induced myocardial injury and heart failure. Possible occurrence of similar adverse reactions in the heart should be considered before choosing piperacillin‑tazobactam as treatment in clinical practice.

13 August 2024 in Skin Research and Technology
Verified
Journal Article
Open access
PLPEILOMG LIU
PEILOMG LIU
QZQuanlin Zhao
Quanlin Zhao
GSGu Shuqing
Gu Shuqing
Background: Increasing studies have reported a causal relationship between androgenetic alopecia (AGA) and lipid‐related metabolites. However, the relationships between HDL‐C, LDL‐C, Omega‐6, and Omega‐3 with AGA remain unclear. Some research findings are even contradictory. Therefore, we designed this study to explore this issue. Methods: In this study, we selected seven exposure factors, screened SNPs with significant associations, removed linkage disequilibrium and weak instrumental variables, and conducted bidirectional MR analysis. Results: The study found that omega‐6 and LDL‐C, especially total cholesterol in medium LDL and total cholesterol in small LDL, are risk factors for the occurrence of androgenetic alopecia. Conclusion: In summary, we found that various lipid‐related metabolites have a causal relationship with the occurrence of androgenetic alopecia, providing new insights into the pathogenesis of androgenetic alopecia and offering references for clinical treatment of androgenetic alopecia.

15 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
FYFan Yang
Fan Yang
QZQuanlin Zhao
Quanlin Zhao
YDYouzi Dong
Youzi Dong
BLBaohua Li
Baohua Li
BNBobiao Ning
Bobiao Ning
Background: Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus (T2DM). It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However, there is no consensus on DPP-4i's pancreatic safety due to a paucity of clinical evidence. The safe event appears to be easily overlooked. This review aims to evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes mellitus using the standard pairwise and network meta-analysis (NMA) methods.Methods: MEDLINE, Embase, Pubmed, Web of Science, and the Cochrane Central Register of Controlled Trials will be used to search for published literature and clinical trial registries (such as www.ClinicalTrials.gov) will be used to look for unpublished trials. English-language randomized controlled trials (RCTs) will be included. Two independent reviewers will screen literature for eligibility, extract available data, and assess the risk of bias. All divergences will be resolved after rechecking the source papers and further discussion among the reviewers with a complete consensus before inclusion. Pancreatic safety events involving acute pancreatitis, chronic pancreatitis, and pancreatic cancer will be the primary outcome. The secondary result will be the change in pancreatic enzyme from the baseline. A random-effects model will be used for pairwise meta-analysis with a 95% confidence interval, and Bayesian network meta-analysis will be conducted between the various interventions.Discussion: This systematic review and network meta-analysis will evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes millitus. The findings of this study may supplement the evidence-based information on DPP-4i, improve existing understanding of this issue, and assist patients and clinicians in making better treatment decisions by raising their awareness of the problem. Systematic review registration: submitted in PROSPERO, 31 August 2021